Alvotech Secures $100M Senior Term Loan to Boost Liquidity and Fund Strategic Growth
ALVO sits 16% above its 52-week low of $4.32 on light trading volume (0.2× avg).
Summary
Alvotech secured a $100 million senior term loan facility with a 12.50% interest rate, enhancing liquidity to fund its R&D pipeline and global product launches through 2026.
Key Events · Financing and Capital Events · ALVO
-
Secured Term Loan Facility
Alvotech announced a new USD 100 million senior term loan facility.
-
Purpose of Funds
The financing is intended to strengthen liquidity and support the execution of strategic priorities, including R&D pipeline advancement and global product launches through 2026.
-
Loan Terms
The loan has a 2-year maturity (December 2027) and bears an interest rate of 12.50%, payable monthly in cash.
-
Replaces Previous Facility
This new term loan replaces the company's previously disclosed working capital facility (ABL), offering enhanced operational flexibility.
Analysis · ALVO · Life Sciences
This financing provides critical capital for Alvotech, a biotechnology company, to advance its R&D pipeline and support global product launches through 2026. While the 12.50% interest rate is substantial, securing this funding strengthens the company's liquidity position and operational flexibility, replacing a previous working capital facility. This move is essential for executing its growth strategy and mitigating near-term funding risks.
At the time of this filing, ALVO was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.32 to $13.70. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.